EIB incentivises bioeconomy investments
The European Investment Bank (EIB) has issued its first Sustainability Awareness Bond worth 500m to support investments into water projects – health and nutrition to follow.
New antibiotics on the block
Around 300 international AMR experts met at ESCMID-ASM drug development conference in Lisbon to discuss the latest progress in the field.
Adaptimmune raises US$100m
Oxford-based Adaptimmune Therapeutics plc has raised US$100m in a registered direct offering of American Depositary Shares (ADS).
CAR-Ts: Novartis wins UK
The NHS England announces it will reimburse Novartis CAR-T cell therapy Kymriah as treatment for children with B cell acute lymphoblastic leukemia (ALL) that are refractory, in relapse post-transplant or in second or later relapse.
Evox raises 37m in Series B round
Exosome drug delivery specialist Evox Therapeutics Ltd has closed a 37.1m (£35.5m) Series B financing round led by Redmile Group and significant contributions from GV (Google Ventures) and Cowen Healthcare Investments.
Sanofi gets the EUs ok for caplacizumab
The EU approved Sanofis Cablivi (caplacizumab) as the first antibody therapeutic to treat acquired thrombotic thrombocytopenic purpura (aTTP) on Friday.
Cancer drug cures orphan disease skin damage
An FDA-approved cancer drug stops light sensitivity of the skin in Cockayne syndrome (CS), an ultra-rare hereditary disease characterised by premature aging, German researchers report.
Germany to pump 1bn into breakthrough innovation
Germanys government announced that it will create an agency for breakthrough ("jump") innovation to foster technology transfer of risky research projects with high market potential into products.
Urovant Sciences licenses OAB gene therapy
Urovant Sciences has licensed the global commercialisation rights for Ion Channel Innovations gene therapy hMaxi-K for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy.
Roche and Affimed in US$5bn cancer deal
Roches US arm Genentech has licenced Affimed NVs ROCK platform to add multivalent antibodies, which could activate the innate immune system, to its cancer pipeline.